Head and Neck Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Immunotherapies and Increasing Prevalence to Drive the Market
No. of Pages: 155
Head and Neck Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Immunotherapies and Increasing Prevalence to Drive the Market
Summary
Head and neck cancer
|
27-Dec-2017
|
4995
|
Cognitive Impairment Disorders Drug Development Pipeline Review, 2018
No. of Pages: 376
Cognitive Impairment Disorders Drug Development Pipeline Review, 2018
Summary
This report provides an overview of the pipeline landscape for cognitive impairment disorders. It provides comprehensive information on
|
01-Apr-2018
|
3995
|
Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2023 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs
No. of Pages: 148
Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2023 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster
|
01-Mar-2018
|
4995
|
Fungal Foot Infections Drug Development Pipeline Review, 2018
No. of Pages: 58
Fungal Foot Infections Drug Development Pipeline Review, 2018
Summary
This report provides an overview of the fungal foot infection pipeline landscape. It provides comprehensive information on the
|
22-Mar-2018
|
3995
|
Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018
No. of Pages: 159
Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018
Summary
This report provides an overview of the non-alcoholic fatty liver disease
|
22-Mar-2018
|
3995
|
Global Neurodegenerative Diseases Drugs Market to 2023 - MS Set to Dominate with Tecfidera and Ocrevus, as Disease-Modifying Pipeline Therapies for Alzheimer’s Disease and SMA Show Clinical and Commercial Potential
No. of Pages: 199
Global Neurodegenerative Diseases Drugs Market to 2023 - MS Set to Dominate with Tecfidera and Ocrevus, as Disease-Modifying Pipeline Therapies for Alzheimer’s Disease and SMA
|
07-Feb-2018
|
4995
|
Uveitis Therapeutics in Asia-Pacific Markets to 2023 - Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline Drugs to Drive the Market
No. of Pages: 91
Uveitis Therapeutics in Asia-Pacific Markets to 2023 - Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline Drugs to Drive the Market
Summary
Uveitis refers to inflammation
|
01-Feb-2018
|
4995
|
Frontier Pharma: Women’s Health - An Expanding Therapy Area, with Endometriosis Therapies Prominent among the First-in-Class Pipeline
No. of Pages: 86
Frontier Pharma: Women’s Health - An Expanding Therapy Area, with Endometriosis Therapies Prominent among the First-in-Class Pipeline
Summary
The women’s health therapy area covers medical disorders that
|
01-Feb-2018
|
6995
|
Global Genetic Disorders Drugs Market to 2023 - A Rapidly Growing Treatment Landscape Driven by Targeted Complement System Inhibitors and Enzyme Replacement Therapies to Treat PNH and Lysosomal Storage Disease
No. of Pages: 160
Global Genetic Disorders Drugs Market to 2023 - A Rapidly Growing Treatment Landscape Driven by Targeted Complement System Inhibitors and Enzyme Replacement Therapies to Treat
|
15-Dec-2017
|
4995
|
COPD Therapeutics in Asia-Pacific Markets to 2023 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Novel Therapies
No. of Pages: 120
COPD Therapeutics in Asia-Pacific Markets to 2023 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Novel Therapies
Summary
Chronic obstructive pulmonary disease (COPD)
|
01-Dec-2017
|
4995
|